NCDC Unveils ₦129bn Lassa Fever Plan as Nigeria Accounts for 92% of West African Cases

Share
Health workers respond as Lassa fever kills 162 Nigerians in 2025

ABUJA, Nigeria – Nigeria will require an estimated ₦129.4bn to implement a five-year strategy aimed at reducing Lassa fever infections and deaths, as the country continues to account for more than 92 per cent of reported cases in West Africa, according to the Nigeria Centre for Disease Control and Prevention (NCDC).

The agency unveiled its National Lassa Fever Strategic Plan 2026–2030 on Friday, outlining measures to strengthen disease surveillance, improve early diagnosis and treatment, expand laboratory capacity and reduce transmission through community-based prevention. The plan identifies Lassa fever as a persistent public health threat, with consequences for healthcare delivery, household livelihoods and national development.

According to the document, West Africa records an estimated 100,000 to 300,000 Lassa fever infections and about 5,000 deaths annually, with Nigeria accounting for more than 92 per cent of reported cases in the region. In the foreword, NCDC Director-General, Dr Jide Idris, said the strategy was designed to improve the country’s response through a coordinated One Health approach that connects human, animal and environmental health systems.

He said the plan drew on more than 57 years of epidemiological evidence and prioritised stronger surveillance, improved case management and community-led prevention. Lassa fever, a viral haemorrhagic disease, is primarily transmitted to humans through contact with food or household items contaminated by the urine or faeces of infected Mastomys rodents. Human-to-human transmission can also occur, particularly in healthcare settings where infection prevention and control measures are inadequate.

The NCDC strategy identifies poor food storage, accumulated household waste and practices that attract rodents as factors contributing to continued transmission.

Join the conversation

Leave a comment

Your email address will not be published. Please keep it civil and on topic.

You May Have Missed